The toxin market changes infrequently. Most clinics settle on a preferred product, a fixed dilution and a familiar injection map, and retain that routine because consistency supports reliable results and patient retention. When a genuinely different product enters the market, it warrants careful review. This article sets out the clinical and practical detail a practitioner needs to assess the newest entrant properly, including how to source it, secure a prescription and manage the patients it is offered to.
What The Product Is
The product discussed here, Alluzience, is the first ready-to-use, pre-mixed liquid botulinum toxin type A licensed in Europe, developed by Ipsen and brought to market by Galderma. Its defining characteristic is the presentation. It is supplied as a liquid, in a vial, ready to inject, which removes reconstitution from the workflow.
Patients often search for Alluzience Botox when researching the treatment, though the product is not Botox at all; Botox is Allergan’s brand of onabotulinumtoxinA, whereas this is a separate type A toxin. For comparison, the other toxins used in the UK, including Azzalure, Bocouture, Botox, Dysport and Letybo, are supplied as freeze-dried powders that require reconstitution before treatment. The liquid formulation removes that step. As a prescription-only medicine it still has to be obtained through a pharmacy against a valid prescription, which practitioners can do through the Faces Pharmacy, covered in more detail later in this article.
You can also read more information about toxins in this related blog: Top 5 Toxin Brands in the UK
Formulation
The formulation is the most clinically significant aspect of any anti-wrinkle injection and the area most often overlooked.
Active substance and unit system
The active substance is botulinum toxin type A (abobotulinumtoxinA), supplied at a concentration of 200 Speywood units per ml. Each vial contains 125 Speywood units in 0.625 ml of solution.
The central point is that Speywood units are not interchangeable with the units of other toxins. A unit of this product is not equivalent to a unit of Botox or Bocouture. Practitioners who already work with Azzalure or Dysport are accustomed to Speywood units, so the dosing framework transfers directly. Those moving from an onabotulinumtoxinA product cannot apply a 1:1 conversion. This is the most common dosing error made when injectors transition between toxin families.
Excipients
The remaining ingredients are L-histidine, sucrose, sodium chloride, polysorbate 80, hydrochloric acid (for pH adjustment) and water for injection.
Of particular note is the absence of human serum albumin and lactose. The product is manufactured using production technology that removes the need for these stabilisers, making it free from human and animal-derived proteins. This is relevant for patients who ask about animal-derived content, those with specific dietary or religious considerations, and those concerned about blood-derived stabilisers. It is a point worth recording on the consent form during the consultation.
Mechanism of action
The toxin acts in the same way as other type A products. At the neuromuscular junction it blocks the release of acetylcholine, preventing the targeted muscle from contracting. The visible smoothing effect is the result of this temporary chemical denervation. The underlying biology is unchanged; the difference lies in the formulation and presentation.
Onset and Duration
Onset and duration are the characteristics patients value most, and the areas where the product differentiates itself.
In the pooled pivotal trials of 372 patients, more than half reported an effect within two to three days, and approximately 23% reported an effect within the first 24 hours. This rapid onset is clinically useful, allowing practitioners to advise first-time patients that softening of movement may be visible within a couple of days.
An effect was demonstrated for up to six months in trials. Responder rates were highest in the first one to two months and declined over time, so six months represents the upper limit rather than a typical outcome. A realistic expectation to set with patients is a reliable three to four months, with the potential for longer in some cases. Recording this expectation clearly within the consultation and consent record supports patient satisfaction at the review appointment.
Alluzience Dosage and Injection Technique
The licensed indication is moderate to severe glabellar lines (with crow’s feet also within scope in the UK product information) in adults under 65.
For the glabellar complex, the recommended dose is 50 Speywood units in total, distributed across five points: two into each corrugator and one into the procerus, at 10 units per point. For lateral canthal lines, the consensus and product guidance specify 30 units per side across three points. Practitioners already injecting Azzalure will recognise this pattern, as it is essentially identical.
Practical considerations include the following:
- The product is a liquid at a fixed concentration, so the injected volume per point is predetermined. This removes the option of selecting a dilution, a flexibility that some experienced injectors value.
- The treatment interval should be no more frequent than every three months. More frequent dosing increases the theoretical risk of neutralising antibody formation, which can reduce the efficacy of subsequent treatments. Spacing appointments correctly is straightforward when bookings are managed through a single scheduling system.
- Storage is refrigerated, 2 to 8°C, and the product must not be frozen. Once opened, it should be used immediately, for a single patient in a single session. Cold-chain handling is required and should be accounted for when ordering stock, which is simpler when sourcing through a pharmacy set up for temperature-controlled supply.
Comparison Summary
Two comparisons come up most often when practitioners assess the product. Alluzience vs Azzalure is not really a contest between different drugs, as both share the same core neurotoxin (aboBoNT-A, Speywood units) and differ only in presentation: Azzalure is a reconstituted powder and the newer option is a pre-mixed liquid. The Alluzience vs Botox comparison is more clear-cut, with the liquid favoured for convenience and speed of onset and Botox favoured for its evidence base and breadth of off-label use. The table below summarises the practical differences.
| Feature | Alluzience | Azzalure | Botox |
|---|---|---|---|
| Manufacturer | Ipsen / Galderma | Ipsen / Galderma | Allergan (AbbVie) |
| Active substance | AbobotulinumtoxinA | AbobotulinumtoxinA | OnabotulinumtoxinA |
| Unit system | Speywood units | Speywood units | Allergan units (not interchangeable) |
| Form | Ready-to-use liquid | Freeze-dried powder | Freeze-dried powder |
| Reconstitution needed | No | Yes | Yes |
| Typical onset | Approx 24 to 72 hours (around 23% within 24h) | Approx 2 to 5 days | Approx 3 to 7 days |
| Duration | Up to 6 months (commonly 3 to 4) | Approx 3 to 4 months | Approx 3 to 4 months |
| Human/animal-derived proteins | Free of human serum albumin and lactose | Contains human serum albumin and lactose | Contains human serum albumin |
| Storage | Refrigerated, 2 to 8°C | Refrigerated, 2 to 8°C | Refrigerated, 2 to 8°C |
| Best suited to | Fast onset, prep-free workflow | Injectors who want dilution control | Established, data-rich first choice |
Onset and duration figures are approximate and vary by patient, dose and technique. Always dose according to the relevant product information and treat units as product-specific.
Alluzience Side Effect Profile and Safety
The safety profile is consistent with other type A toxins. The documented profile from the clinical trials lists headache and injection-site reactions (bruising, swelling, redness, tenderness, tingling) as very common, with eyelid ptosis, brow ptosis, dry eye and facial paresis in the less common category. The majority of reported reactions were mild to moderate and reversible, and their incidence tended to decrease with repeated treatment cycles.
The rare but serious risk common to all botulinum toxins is spread of effect beyond the injection site. Standard mitigations apply: correct technique, the lowest effective dose, careful patient selection and adherence to contraindications, including pregnancy, breastfeeding, neuromuscular disorders and infection at the injection site. Capturing these checks within a structured consent record protects both the patient and the practitioner, and is one reason many clinics run consultation, consent and treatment notes through a single platform like Faces.
A practical observation reported by injectors is that some patients perceive the liquid as slightly more uncomfortable on injection than a reconstituted powder. This is worth noting at consultation for needle-averse patients.
Alluzience Reviews and Clinical Reputation
Patients frequently attend having viewed Alluzience before and after galleries and read clinic feedback online, so an awareness of the published data is useful. In trials, 85.2% of treated patients were satisfied or very satisfied at one month, compared with 9% on placebo. Practitioner feedback broadly aligns with this, with rapid onset and natural-looking results being the most frequently cited strengths.
Pricing and Stocking
Commercial considerations form part of the decision. The Alluzience Botox price practitioners look up reflects trade pricing that is broadly comparable to other premium toxins on a per-treatment basis, and the fast onset and extended-duration positioning allow many clinics to apply a modest premium at the patient level. The Alluzience price to a prescriber, and the Alluzience cost per vial, vary with supplier, pack size and VAT, so any fixed figure would quickly become outdated. Current trade pricing should be confirmed before the product is added to a menu.
You can check current stock and pricing on our shop.
Sourcing, Prescribing and Booking through Faces Consent
Adding a new toxin involves more than the product itself. It requires a compliant prescription, a reliable pharmacy supply, proper consent records and a way to manage patient bookings. We bring these elements together in a single platform, which removes much of the administrative friction of introducing a new product into a clinic.
A pharmacy to purchase toxins
We give practitioners access to our own Faces Pharmacy alongside a network of partner pharmacies, all through a single platform. This means toxins and associated stock can be ordered in one place, with the choice of supplier that a multi-pharmacy network provides, rather than maintaining separate accounts across multiple suppliers. You can source this product and other injectables with cold-chain handling and current pricing managed through the platform.
Access to prescribers
For non-prescribing injectors, the most significant barrier is securing a lawful prescription following a face-to-face consultation. We allow practitioners to connect and communicate with prescribers directly, making it straightforward to find a prescriber and arrange the prescription needed to obtain the product.
Booking and consent in one place
Our platform also handles patient bookings and digital consent forms, allowing client records, appointments and consent to sit alongside stock and prescriptions. Managing these functions in one system supports both clinic efficiency and the audit trail expected in regulated practice.
Everything Your Clinic Needs, One Login
Faces Consent is a complete platform for aesthetic practitioners, combining our own Faces Pharmacy and partner pharmacy network for purchasing toxins, the ability to connect and communicate with prescribers, and built-in patient booking and consent management.
Ready to add Alluzience to your treatment menu? Order Alluzience and manage your clinic in one place through Faces Consent, where stock, prescribers, bookings and consent all sit under one login.
Summary
The product is not a fundamental redesign of botulinum toxin treatment. It is a toxin many clinics already trust, presented in a form that is faster to prepare and quicker to show results. For practitioners who wish to remove reconstitution variability, or who serve a patient base that values rapid onset, it is a sound addition. The recommended approach is to gain experience with it on a limited number of cases before adopting it more widely, supported by a reliable supply route, straightforward access to a prescriber and a single system for managing bookings and consent.
FAQs
Is the product licensed in the UK?
Yes. It is a prescription-only medicine, MHRA-regulated, licensed for moderate to severe glabellar lines (with crow’s feet within scope under the UK product information) in adults under 65. As with any toxin, it must be prescribed and administered by an appropriately qualified practitioner. Non-prescribers can connect with a prescriber through our platform to arrange this.
Is Alluzience better than Botox?
It depends on the priority. The liquid offers superior convenience and a faster onset within the first 24 to 72 hours, while Botox is the most extensively studied toxin available and the one most injectors have the longest experience dosing accurately. There is no universally superior toxin; the right choice depends on the clinic’s workflow and patient base.
How quickly will patients see results compared with other toxins?
More quickly than most. In trials, over half of patients noticed an effect within two to three days, and approximately a quarter within 24 hours. Patients should still be advised that full settling takes up to two weeks, as with any toxin.
How should it be stored, and how long does an opened vial last?
Refrigerate at 2 to 8°C, do not freeze, and keep the vial in its original carton. Once opened it should be used immediately, for a single patient in a single session. Any unused product must be disposed of rather than retained. As a cold-chain product, deliveries require appropriate planning, which is simpler when ordering through a pharmacy equipped for temperature-controlled supply.
How should it be stored, and how long does an opened vial last?
Refrigerate at 2 to 8°C, do not freeze, and keep the vial in its original carton. Once opened it should be used immediately, for a single patient in a single session. Any unused product must be disposed of rather than retained. As a cold-chain product, deliveries require appropriate planning, which is simpler when ordering through a pharmacy equipped for temperature-controlled supply.